Table 4 PET2 SUVmean and change in SUVmean in healthy tissue with PFS.

From: Healthy tissue metabolism assessed by [18F]FDG PET/CT as a marker of prognosis and adverse events in advanced Hodgkin lymphoma patients

Tissue of interest

PET2 and PFS

Change and PFS

Events/N

HR (95% CI)*

p-value

Events/N

HR (95% CI)∆

p-value

BM

 

 PET2−

32/150

0.72 (0.48–1.08)

0.11

32/150

0.91 (0.79–1.05)

0.19

 PET2+

20/46

2.31 (1.12–4.75)

0.023

20/46

1.18 (0.95–1.48)

0.13

Spleen

 

 PET2−

49/188

0.87 (0.45–1.70)

0.69

29/142

0.85 (0.71–1.02)

0.085

 PET2+

20/46

1.25 (0.91–1.71)

0.16

Liver

52/195

1.25 (0.65–2.43)

0.50

52/195

1.09 (0.98–6.69)

0.09

MBP

52/196

1.32 (0.53–3.32)

0.55

52/196

1.07 (0.95–1.20)

0.25

  1. Significant values are in bold.
  2. SUVmean values were analysed as continuous variables (HRs shown are for a unit increase (*) or an increase of 10% from PET0 to PET2 (∆)) and were adjusted for treatment regimen (ABVD/AVD or BEACOPP) and, for analyses of change (∆), also adjusted for the PET2 SUVmean value. The interaction between the SUVmean and the response was also considered. This was significant (p = 0.006(*)/p = 0.027(∆) for BM and for spleen (p = 0.040 (∆ only)) therefore this is presented separately for PET− and PET2 + patients. PFS progression-free survival, HR hazard ratio, N number, CI confidence interval, BM bone marrow, MBP mediastinal blood pool.
Back to article page